BioMarin Pharmaceutical (BMRN) Competitors $57.68 -0.98 (-1.67%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$57.37 -0.31 (-0.54%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. BIIB, INCY, UTHR, NBIX, EXEL, MDGL, EXAS, HALO, RGEN, and IONSShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis Madrigal Pharmaceuticals Exact Sciences Halozyme Therapeutics Repligen Ionis Pharmaceuticals BioMarin Pharmaceutical (NASDAQ:BMRN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Which has higher earnings and valuation, BMRN or BIIB? Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$3.06B3.62$426.86M$3.3717.12Biogen$9.68B2.01$1.63B$10.4612.68 Is BMRN or BIIB more profitable? BioMarin Pharmaceutical has a net margin of 21.45% compared to Biogen's net margin of 15.31%. Biogen's return on equity of 13.85% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical21.45% 12.59% 10.13% Biogen 15.31%13.85%8.32% Do analysts recommend BMRN or BIIB? BioMarin Pharmaceutical presently has a consensus price target of $93.17, suggesting a potential upside of 61.54%. Biogen has a consensus price target of $185.74, suggesting a potential upside of 40.02%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.72Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34 Do institutionals & insiders have more ownership in BMRN or BIIB? 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to BMRN or BIIB? In the previous week, Biogen had 28 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 47 mentions for Biogen and 19 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.42 beat Biogen's score of 1.12 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 27 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, BMRN or BIIB? BioMarin Pharmaceutical has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. SummaryBioMarin Pharmaceutical beats Biogen on 11 of the 16 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.26B$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio17.1221.0831.2726.59Price / Sales3.62350.65433.65155.40Price / Cash18.0744.6737.7359.36Price / Book1.848.0910.176.68Net Income$426.86M-$54.08M$3.27B$265.59M7 Day Performance-1.54%-0.41%1.39%0.62%1 Month Performance-0.94%6.23%6.19%2.61%1 Year Performance-36.87%10.45%43.79%22.34% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9963 of 5 stars$57.68-1.7%$93.17+61.5%-36.1%$11.26B$3.06B17.123,040Positive NewsBIIBBiogen4.8159 of 5 stars$135.91-1.9%$185.74+36.7%-35.0%$19.93B$9.68B12.997,605Positive NewsINCYIncyte4.6696 of 5 stars$84.92-2.3%$81.20-4.4%+27.5%$16.58B$4.24B19.302,617Positive NewsUTHRUnited Therapeutics4.9273 of 5 stars$314.10+0.3%$382.00+21.6%-14.6%$14.17B$2.88B12.261,305Positive NewsNBIXNeurocrine Biosciences4.844 of 5 stars$133.14+0.2%$160.90+20.9%+12.3%$13.20B$2.36B39.391,800Positive NewsEXELExelixis4.8782 of 5 stars$37.76-1.4%$44.06+16.7%+46.8%$10.16B$2.17B18.151,147Trending NewsAnalyst DowngradeMDGLMadrigal Pharmaceuticals3.8891 of 5 stars$391.43+5.8%$439.71+12.3%+74.3%$8.69B$180.13M-30.4690Positive NewsAnalyst ForecastHigh Trading VolumeEXASExact Sciences4.9362 of 5 stars$45.09-1.1%$67.43+49.5%-23.2%$8.54B$2.76B-8.307,000Positive NewsHALOHalozyme Therapeutics4.7061 of 5 stars$68.96+2.5%$67.11-2.7%+13.0%$8.07B$1.02B15.78390Positive NewsRGENRepligen4.8619 of 5 stars$124.08-0.2%$169.45+36.6%-16.0%$6.98B$673.96M-496.301,778Positive NewsIONSIonis Pharmaceuticals4.6263 of 5 stars$43.43-0.8%$59.38+36.7%-13.5%$6.92B$944.05M-23.601,069Options Volume Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors EXEL Competitors MDGL Competitors EXAS Competitors HALO Competitors RGEN Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access